WuXi Biologics maintains operational bases in China and leverages a global CRDMO network for client support.
4 reports, 3 independent
Updated Aug 30
Gone quiet
- Reports
- 4
- Developments
- 3
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
WuXi Biologics maintains operational bases in China and leverages a global CRDMO network for client support.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- WuXi Biologics facility passed GMP inspection with zero critical findings, leading to EMA support for EU marketing authorization.Sub-event
- DP15 achieved GMP release in April by leveraging the global CRDMO network capabilities.Sub-event
WuXi Biologics maintains operational bases in China and leverages a global CRDMO network for client support.1 source
Keep exploring
The entities involved
-
China
cultural region, ancient civilization, and nation in East Asia; mostly refers to the People's Republic of China in political situation and rarely refers to the Republic of China
-
WuXi Biologics
Chinese pharmaceutical company